HTFL
Heartflow, Inc.
$26.72
-1.00 (-3.61%)
At close · Jul 10
Market Cap
$2.30B
Shares
86,240,828
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.72
Open$27.75
Day$26.29–28.35
52W$20.13–41.22
Avg vol 30d1.8M
Short int5.2M · 6.0% float · 1.7d
Short vol58%
Last earningsMay 14, 2026
DataAug 2025–Jul 2026
Filing10-Q · May 14
Up next
Next earnings call
Aug 14, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−11%
below
Price vs 50-day avg
−11%
below
RSI (14)
39
neutral
MACD trend
Negative
52-week position
31%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−9%
trailing
6-month return
−26%
trailing
YTD return
−8%
this year
Relative strength
−35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $30 › 200d $30 — 50d above 200d
Institutional flow
Accumulating
7 of 168 funds reported for Jun 30 · net +20.1K sh shares · +2 new
Insider flow
Distributing
Net -$60.5M over 90 days · 100% sells
Short interest
Rising
6.00% of float · ▲ +22.9% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
168 holders — 13F breadth
Squeeze score
57
elevated · 0–100
Fundamentals
Revenue growth
+40%
Y/Y
Gross margin
77%
expanding
EPS growth
+82%
Y/Y
Free cash flow
$-59.0M
Valuation
P/E 15.2
below peers
Balance sheet
$44.8M
net cash
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
8.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 14, 2026
Total revenue
· Full Year 2026
Maintained
$228M – $232M
prior FY $176.03M
midpoint +30.7% Y/Y
Non-GAAP gross margin
· Full Year 2026
Non-GAAP
Initiated
81%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−11%
Bearish
Price vs 50-day avg
−11%
Bearish
RSI (14)
39
Neutral
MACD trend
Negative
Bearish
52-week position
31%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $30 › 200d $30 — 50d above 200d
Institutional flow
Accumulating
7 of 168 funds reported for Jun 30 · net +20.1K sh shares · +2 new
Insider flow
Distributing
Net -$60.5M over 90 days · 100% sells
Short interest
Rising
6.00% of float · ▲ +22.9% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
168 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $20
Now $27 · 31%
52-wk high $41
vs 200-day avg -11%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP gross margin non-GAAP | 80.5% | Q1 2026 | — |
|
|
|||
| Non-GAAP net operating loss non-GAAP | $15.5M | Q1 2026 | — |
|
|
|||
| annotated CCTA images in proprietary dataset | 200M | Q1 FY2026 call | — |
| clinical studies and trials | 200 | Q1 FY2026 call | — |
| global case growth | 67% | Q1 FY2026 call | — |
| incremental U.S. TAM from upcoming RCTs | $6B | long-term call | — |
| medical education events focused on plaque (last 12 months) | 1,000 | last 12 months call | — |
| Navigate PCI registry patient enrollment target | 5,000 | Q1 FY2026 call | — |
| new accounts added in 2025 | 340 | FY2025 call | — |
| patients managed worldwide | 650,000 | Q1 FY2026 call | — |
| peer-reviewed publications | 625 | Q1 FY2026 call | — |
| physician impressions from medical education events | 100,000 | last 12 months call | — |
| total addressable market | $11B | long-term call | — |
| total global revenue cases | 67,443 | Q1 FY2026 call | — |
| total U.S. covered lives for Plaque | 75% | as of December 31, 2025 | — |
| U.S. installed base | 1,465 | as of December 31, 2025 | — |
| U.S. Plaque installed base | 489 | as of December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HTFL
this stock
Heartflow, Inc.
|
$2.30B | -8.3% | +39.9% | 15.2 | 6.0% |
|
VEEV
Veeva Systems Inc
|
$30.88B | -14.8% | +28.1% | 33.7 | 4.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$15.67B | -9.4% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$13.85B | +90.7% | -0.4% | 51.0 | 6.6% |
|
TEM
Tempus AI, Inc.
|
$10.46B | -1.4% | +65.8% | — | 18.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HTFL | -4.5% | -9.2% | -26.0% | -8.9% | -8.3% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -5.8% | -13.3% | -35.1% | -10.0% | -19.1% |